Biogen Inc BIIB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 05/21/24 EDT

227.69

-3.89 (-1.68%)

Volume

716,665

52 week range

189.44 - 319.76

Open0.00
Day High0.00
Day Low0.00
Prev Close227.69
52 Week High319.76
52 Week High Date06/12/23
52 Week Low189.44
52 Week Low Date04/19/24

Key Stats

Market Cap33.151B
Shares Out145.60M
10 Day Average Volume1.02M
Dividend-
Dividend Yield-
Beta-0.01
YTD % Change-12.01

KEY STATS

Open0.00
Day High0.00
Day Low0.00
Prev Close227.69
52 Week High319.76
52 Week High Date06/12/23
52 Week Low189.44
52 Week Low Date04/19/24
Market Cap33.151B
Shares Out145.60M
10 Day Average Volume1.02M
Dividend-
Dividend Yield-
Beta-0.01
YTD % Change-12.01

RATIOS/PROFITABILITY

EPS (TTM)8.00
P/E (TTM)28.45
Fwd P/E (NTM)14.79
EBITDA (TTM)2.652B
ROE (TTM)8.04%
Revenue (TTM)9.663B
Gross Margin (TTM)75.03%
Net Margin (TTM)12.08%
Debt To Equity (MRQ)42.99%

EVENTS

Earnings Date07/23/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Biogen Inc

Lightning Round: We're only in the middle of Micron's roll higher, says Jim CramerMay 10, 2024CNBC.com
Cramer's Lightning Round: Bank of America is a buyMay 10, 2024CNBC.com
Lilly assures investors it can overcome the high-quality problem of too much demandApril 30, 2024CNBC.com
3-Stock Lunch: TXN, BIIB & CMGApril 24, 2024CNBC.com
Stocks making the biggest moves midday: Tesla, Hilton, Boeing, Mattel and moreApril 24, 2024CNBC.com

Content From Our Affiliates

Biogen: A Balanced View Amidst Setbacks and Alzheimer’s Drug PotentialMay 16, 2024TipRanks
Biogen (BIIB) Receives a Buy from Truist FinancialMay 16, 2024TipRanks
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 16, 2024TipRanks
Biogen, Ionis terminate development of BIIB105 based on data from ALSpire studyMay 16, 2024TipRanks
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)May 15, 2024TipRanks

Profile

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include...

Caroline Dorsa

Independent Chairman of the Board

Christopher Viehbacher

President, Chief Executive Officer, Director

Michael McDonnell CPA

Chief Financial Officer, Executive Vice President

Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

Adam Keeney Ph.D.

Executive Vice President, Head of Corporate Development

Address

225 Binney Street

Cambridge, MA

02142

United States

https://www.biogen.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
MRNA Moderna Inc	143.69	+2.68	+1.90%
ILMN Illumina Inc	107.61	-0.92	-0.85%
GRFS Grifols SA	7.67	-0.01	-0.13%
BNTX Biontech SE	92.07	-0.40	-0.43%
GMAB Genmab A/S	29.15	-0.54	-1.82%